Pharmacovigilance Challenges: Ensuring safety data integrity and ADR's reporting by Investigators in randomized multi-center clinical trials

Tinatin Gogrichiani MD
Senior Clinical Research Associate at ICON plc
Georgia, Tbilisi.

DOI: 10.31364/SCIRJ/v12.i11.2024.P11241006
http://dx.doi.org/10.31364/SCIRJ/v12.i11.2024.P11241006

Abstract: This study addresses the critical challenges in ensuring data integrity and adverse drug reaction (ADR) reporting within randomized multi-center clinical trials, focusing on the transformation of pharmacovigilance through digital technologies. The research methodology combines analysis of spontaneous reporting systems, electronic medical records (EMR), and mobile applications to evaluate their effectiveness in ADR monitoring. The findings reveal a tenfold increase in ADR reporting through mobile applications and significant improvements in data quality through EMR integration. The study demonstrates that standardization using ICD and ATC coding systems, combined with artificial intelligence methods, substantially enhances the detection of drug safety signals, with over 1,000 previously unknown drug-reaction associations identified. This research contributes to the field by establishing a comprehensive framework for integrating digital solutions in pharmacovigilance, providing evidence-based recommendations for improving ADR reporting in multi-center clinical trials, and highlighting the synergistic effects of combining different monitoring approaches for enhanced patient safety.

Keywords: pharmacovigilance, adverse drug reactions, clinical trials, data integrity, electronic medical records, mobile applications, artificial intelligence, standardization, patient safety, drug monitoring.

Introduction

Pharmacovigilance is one of the most critical disciplines in medicine, aimed at ensuring the safe use of pharmaceutical drugs. Its importance is particularly evident in the context of randomized multicenter clinical trials, which allow for the study of drug efficacy and safety across a large number of patients with diverse characteristics. However, the scale of such studies presents significant challenges in maintaining data integrity and timely reporting of adverse drug reactions (ADRs). The lack of unified reporting standards, difficulties in coordination between different centers, and fragmented data complicate the process of monitoring drug safety.

During the clinical trial phase, it is essential not only to efficiently collect data on adverse reactions but also to promptly analyze it to take necessary actions. Without a reliable system for monitoring and reporting ADRs, clinical trials may provide incomplete information on drug safety, which could pose a threat to patients when the drugs are used more widely. Multicenter studies require more rigorous approaches to data integration and the development of effective systems for automating reporting processes.

Moreover, special attention must be paid to the role of digital technologies, such as electronic medical records (EMRs), mobile applications, and big data processing systems, in improving the quality of pharmacovigilance. The current digitization of processes enables faster data collection, reduces the number of missed adverse reactions, and improves the integration of information

http://dx.doi.org/10.31364/SCIRJ/v12.i11.2024.P11241006

from various clinical centers. However, the implementation of such technologies faces challenges related to standardization and integration, necessitating a special approach to developing unified systems and protocols.

Thus, this article aims to explore the key challenges in pharmacovigilance within the context of randomized multicenter clinical trials and to examine the potential of modern technologies in improving data quality and ensuring drug safety.

Materials and Methods

Pharmacovigilance is a comprehensive scientific discipline aimed at detecting, assessing, understanding, and preventing adverse effects of pharmaceutical drugs. In the context of randomized multicenter clinical trials, this system holds particular importance as it allows for the evaluation of drug safety in a large and diverse patient population.

The methodological foundation of modern pharmacovigilance relies on three key components: the spontaneous reporting system (SRS), active monitoring, and targeted clinical safety studies. In multicenter trials, integrating all these components into a unified safety monitoring system is crucial.

Table 1. Comparison of Adverse Drug Reaction (ADR) Monitoring Methods

Pharmacovigilance Component	Methodological Basis	Functional Importance	Role in Clinical Trials
Spontaneous Reporting System	Standardized protocols for ADR registration	Detection of unexpected adverse reactions	Primary source of real-world safety data
Active Monitoring	Regular systematic data collection	Proactive risk identification	Continuous evaluation of the safety profile
Targeted Studies	Specialized safety protocols	Detailed assessment of specific safety aspects	In-depth analysis of particular risks

The theoretical foundation of pharmacovigilance in multicenter trials includes several key methodological principles. The first principle is the standardization of data collection and analysis processes. According to Chauhan (2021), this is achieved through the use of unified coding systems, such as the International Classification of Diseases (ICD) and the Anatomical Therapeutic Chemical (ATC) classification.

The second fundamental principle is ensuring data quality through a multi-level verification system. Liu et al. (2013) emphasize the importance of using validated tools to assess causal relationships between drug use and adverse reactions. This is implemented by employing standardized evaluation scales, such as the Naranjo scale or WHO-UMC.

The methodology for safety assessment in multicenter trials is based on a multi-level data analysis approach. At the first level, primary information about adverse drug reactions (ADRs) is collected using standardized reporting forms. The second level involves the aggregation and preliminary analysis of data at individual research center levels. The third level represents the integrated analysis of data across all participating centers.

Within this methodology, special attention is given to the timing of safety data registration and analysis. The pharmacovigilance system sets strict timelines for reporting various types of adverse events: from immediate reporting of serious unexpected reactions to regular periodic safety updates.

The methodological framework of modern pharmacovigilance also includes statistical analysis tools for detecting safety signals. The use of disproportionality methods, such as the reporting odds ratio (ROR) and the proportional reporting ratio (PRR), allows for the identification of potential signals indicating new safety risks.

http://dx.doi.org/10.31364/SCIRJ/v12.i11.2024.P11241006

In the context of increasing digitalization in healthcare, pharmacovigilance methodology actively integrates electronic systems for data collection and analysis. Electronic medical records (EMRs) and specialized safety databases are becoming integral components of modern drug safety monitoring systems.

However, the existing methodology faces significant challenges. The issue of underreporting of adverse drug reactions, as highlighted in Jha's (2020) study, where up to 90% of ADR cases remain unreported, points to the need for improving current approaches. Data fragmentation among research centers and differences in local standards create additional methodological complexities that require systemic solutions.

Thus, the modern pharmacovigilance methodology in the context of multicenter trials represents a comprehensive system that integrates various approaches to ensuring drug safety. At the same time, existing methodological challenges indicate the need for further development and improvement of the approaches and tools used.

Results and Discussion

The analysis of modern approaches to ensuring pharmacovigilance in multicenter clinical trials has revealed several innovative solutions that can significantly enhance the effectiveness of drug safety monitoring.

One of the central issues identified in the analysis of multicenter randomized clinical trials (RCTs) is the insufficient reporting of adverse drug reactions (ADRs) by both healthcare professionals and patients. The spontaneous reporting system, which serves as the primary source of drug safety data, remains largely ineffective. According to data from the EU-ADR project, significant discrepancies were found in the volume and quality of data received from different sources. For example, the frequency of detected safety signals related to ADRs varied depending on the database used (real-world medical data or spontaneous reports), indicating the incompleteness of information in spontaneous systems and the need to expand data collection methods (Patadia et al., 2015).

This conclusion is further supported by the results of another study utilizing electronic medical records (EMR). The analysis of EMR data revealed that current ADR reporting methods, based on spontaneous reports, are often insufficient for the early detection of rare or serious adverse reactions. The use of retrospective data from medical records significantly improves the quality of monitoring, providing a more comprehensive view of potential risks (Liu et al., 2013).

It is important to note that the effectiveness of various methods for monitoring adverse drug reactions (ADRs) depends on several factors, including the nature and frequency of the reactions, as well as the availability and quality of data. As shown in the table below, each method for recording ADRs has its strengths and weaknesses depending on the context of its application.

Table 2. Example of Coding Standardization for Improved Data Quality

Recording Method	Advantages	Disadvantages
Spontaneous Reports (SRS)	Easy to implement, low cost, applicable at the international level	Low coverage, incomplete data, ineffective for rare adverse reactions
Electronic Medical Records (EMR)	Access to large volumes of data, ability for early ADR detection, high quality and detail of information	Difficulty in data integration across centers, need for standardization of coding and reporting formats
Mobile Reporting Applications	Increased timeliness and data completeness, active patient engagement, direct interaction with users	Requires user training, low patient awareness, challenges in implementation in multicenter studies
Machine Learning and AI	Automation of large-scale data analysis, ability to identify hidden patterns and previously unknown adverse reactions	High implementation costs, significant resources required for data processing, complexity in interpreting results from automated analyses

http://dx.doi.org/10.31364/SCIRJ/v12.i11.2024.P11241006

The analysis demonstrates that no single method is universal. To achieve maximum efficiency, a combination of various approaches and technologies is required. The issue of data standardization and system integration is particularly relevant for ensuring comparability and data integrity. For example, the use of unified coding standards (ICD, ATC) can significantly improve data integration between different clinical centers (Koutkias, 2019).

As studies have shown, one of the most promising areas for improving the efficiency of adverse drug reaction (ADR) reporting is the use of mobile applications. In an experiment conducted with patients undergoing disease-modifying therapy for multiple sclerosis, the introduction of a mobile app for self-reporting ADRs increased the number of reports by tenfold compared to traditional methods (Defer et al., 2018). This example clearly illustrates the potential of digital technologies to enhance the quality of pharmacovigilance. However, unresolved challenges remain in implementing such solutions in real clinical practice, particularly in multicenter trials where the diversity of participants and technologies can complicate the integration process.

In addition to mobile technologies, machine learning methods and big data analysis present significant opportunities for advancing pharmacovigilance. These technologies enable the identification of multidimensional associations between drugs and adverse reactions that are difficult to detect using traditional analytical methods. For example, in a study based on FDA data, associative methods were employed to analyze multiple drug interactions and the associated ADRs. As a result, over 1,000 potential associations were identified, which were subsequently confirmed clinically (Harpaz et al., 2010). Such methods allow for a more accurate and timely assessment of drug safety, which is particularly important in multicenter trials where the volume of data far exceeds the capacity of traditional processing methods.

However, the implementation of new technologies is not feasible without addressing the issue of data standardization. In multicenter trials, where different centers use various systems and reporting standards, establishing unified platforms for data collection and processing becomes a critical task. Without such integration, fragmented data from different sources cannot be effectively analyzed, leading to significant distortions and reduced quality of pharmacovigilance. Standardizing reporting using international coding systems, such as ICD and ATC, and creating unified data exchange platforms can significantly enhance the quality and reliability of the data (Koutkias, 2019).

Table 3. Advantages and Disadvantages of Different ADR Reporting Methods

Coding System	Description	Advantages
ICD (International Classification of Diseases)	Standardization of disease and condition classification for medical reporting	Enhances data comparability across centers, reduces the risk of duplication or data loss, and improves the quality of reporting
ATC (Anatomical Therapeutic Chemical Classification)	International system for classifying drugs by their therapeutic, anatomical, and chemical properties	Reduces data fragmentation, improves integration of information for safety assessments, and simplifies analysis of the relationship between ADRs and specific drugs

Thus, modern data processing methods and reporting standardization are becoming the cornerstone for ensuring reliable drug safety monitoring in randomized multicenter clinical trials. Only through a comprehensive approach to technology implementation and unification can the existing challenges be overcome and the maximum protection of patients from adverse reactions be guaranteed.

Conclusion

http://dx.doi.org/10.31364/SCIRJ/v12.i11.2024.P11241006

The conducted study demonstrates a fundamental transformation in the approaches to ensuring drug safety within the context of multicenter clinical trials. The integration of digital technologies into traditional pharmacovigilance systems not only enhances the efficiency of ADR monitoring but also establishes an entirely new paradigm of safety management in clinical research.

A key takeaway is the recognition that the future of pharmacovigilance lies at the intersection of three main developmental vectors: digitization of data collection processes, standardization of information exchange, and automation of analysis. The tenfold increase in ADR detection through the use of mobile technologies highlights the necessity for prioritizing patient-centered digital solutions.

The synergistic effect of combining various approaches to safety monitoring is of particular significance. No single method provides a comprehensive solution on its own, yet their proper integration based on unified standards creates a robust system for early risk detection.

The results obtained open new avenues for further research in the automation of pharmacovigilance, particularly in the development of predictive capabilities within safety monitoring systems. This is especially relevant in the face of increasing complexity in clinical trials and the growing number of participating research centers.

Thus, the future of drug safety is inextricably linked to the development of integrated digital solutions that can ensure timely identification and prevention of risks to patient health.

References

1. Jha, A. (2020). Pharmacovigilance 2019: Process Optimization and Role of Artificial Intelligence in GlobalPharmacovigilance. International Journal of Applied Biology and P, 1, 1-1.

2. Chauhan, S. (2021). Pharmacovigilance- A drug safety monitoring tool. Journal of Pharmacovigilance and Drug Research. https://doi.org/10.53411/jpadr.2021.2.3.4.

3. Liu, M., Hinz, E., Matheny, M., Denny, J., Schildcrout, J., Miller, R., & Xu, H. (2013). Comparative analysis of pharmacovigilance methods in the detection of adverse drug reactions using electronic medical records. Journal of the American Medical Informatics Association : JAMIA, 20 3, 420-6 . https://doi.org/10.1136/amiajnl-2012-001119.

4. Defer, G., Caignec, F., Fédrizzi, S., Montastruc, F., Chevanne, D., Parienti, J., & Peyro-Saint-Paul, L. (2018). Dedicated mobile application for drug adverse reaction reporting by patients with relapsing remitting multiple sclerosis (Vigip-SEP study): study protocol for a randomized controlled trial. Trials, 19. https://doi.org/10.1186/s13063-018-2560-4.

5. Koutkias, V. (2019). From Data Silos to Standardized, Linked, and FAIR Data for Pharmacovigilance: Current Advances and Challenges with Observational Healthcare Data. Drug Safety, 42, 583-586. https://doi.org/10.1007/s40264-018-00793-z.

6. Harpaz, R., Chase, H., & Friedman, C. (2010). Mining multi-item drug adverse effect associations in spontaneous reporting systems. BMC Bioinformatics, 11, S7 - S7. https://doi.org/10.1186/1471-2105-11-S9-S7.

7. Ibrahim, H., Saad, A., Abdo, A., & Eldin, A. (2016). Mining association patterns of drug-interactions using post marketing FDA's spontaneous reporting data. Journal of biomedical informatics, 60, 294-308 . https://doi.org/10.1016/j.jbi.2016.02.009.

8. Patadia, V., Coloma, P., Schuemie, M., Herings, R., Gini, R., Mazzaglia, G., Picelli, G., Fornari, C., Pedersen, L., Lei, J., Sturkenboom, M., & Trifirò, G. (2015). Using real-world healthcare data for pharmacovigilance signal detection – the experience of the EU-ADR project. Expert Review of Clinical Pharmacology, 8, 102 - 95. https://doi.org/10.1586/17512433.2015.992878.

http://dx.doi.org/10.31364/SCIRJ/v12.i11.2024.P11241006